image 1
image 2
image 4
image 7
image 6
image 3
image 8
image 5

The Rappaport Institute looks forward to continuing to make substantial future contributions in biomedical research"

Professor Karl Skorecki

Technologies

Disease AreasBiopharmaceuticalMedical DevicesMedical DiagnosticsPersonalized TechnologiesBio Research ToolsOthers
 
Home » Media Center » Press Releases » Archive
Press Releases
|

Archive

18 November, 2008 Synvista Therapeutics, Inc Announced on the 18th of November, 2008, that it has applied for FDA clearance for its revolutionary HAPTOCHEK diagnostic test kit
22 July, 2008 Mr. Benjamin Soffer has been appointed as a director at BioRap, replacing Prof. Zvi Kohavi
27 December, 2007 Israeli scientists identify genes that affect multiple sclerosis (MS) patients' responses to copaxone
Weizmann Institute Press ReleaseLink
26 November, 2007 Vitamin E could help 40% of diabetics ward off heart attacks
5 November, 2007 Synvista Collaboration Demonstrates in Preclinical Studies, the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
5 November, 2007 Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
25 September, 2007 Bio-Rap completes first trial of Type 1 diabetes detection biomarker
24 May, 2007 Rappaport Institute and BioRap members, Profs. Michael Aviram and Gera Neufeld receive Herschel Rich Innovation Awards for the year 2007
24 May, 2007 Micromedic signs term sheet with BioRap to develop and market new devices for the early detection of diabetes
Micromedic seeks to raise capital - English translation: (27.0 Kb)Download
4 May, 2007 Alteon Expands Licensing Agreement With Biorap Technologies for Diagnostic Assays That Identify High Risk Cardiovascular Patients
14 March, 2007 Haptoglobin Genotype Determines Myocardial Infarct Size in Diabetic Mice
15 January, 2007 Technion Prominent in Stem Cell Research
13 November, 2006 Alteon's ALT-2074 Demonstrates Ability to Reduce Infarct Size by 80 Percent in Mice with Haptoglobin 2-2 Genotype
19 April, 2006 Alteon and HaptoGuard Shareholders Approve Merger
20 March, 2006 Prof. Kohavi has been appointed as a director at BioRap
20 June, 2005 BioRap Technologies Ltd signs development and commercialization agreement with Biolinerx for therapeutic treatment of prostate cancer
16 May, 2005 BioRap Technologies Ltd Signs Agreement With HaptoGuard
10 October, 2004 Professors Avram Hershko and Aaron Ciechanover Winners of the 2004 Nobel Prize in Chemistry
Visit Nobel Prize siteLink
1 January, 2004 Ruth Alon of Pitango appointed to the Board of Directors of BioRap
23 March, 2003 ARUP gets a license to HaptoGuard Diagnostic Test

Haptoglobin Typing

Report an Invention

For BioRap InventorsFunding Opportunities

Rappaport Institute

The Rappaport InstituteNobel Prize
Copyright © 2014 BioRap Technologies LTD. All Rights Reserved. Created by Catom web design